http://orcid.org/0000-0001-8993-0981
References
- O’Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894–900.
- O’Connor PW, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–1303.
- Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13:247–256.
- Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing and remitting multiple sclerosis. Neurol Ther. 2014 Nov 20;3:133–139.
- Miller A, Turpault S, Menguy-Vacheron F. Rapid elimination procedure of teriflunomide with cholestyramine or activated charcoal. Poster session presented at: the fourth cooperative meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis. San Diego, CA. 2012 May 30–Jun 2.
- Insull W Jr, Davidson MH, Demke DM, et al. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20;112(2):223–235.
- Lunven C, Guo Z, Turpault S, et al. Effectiveness and tolerability of colesevelam HCl for accelerated elimination of teriflunomide in healthy participants. J Clin Pharmacol. 2017 Jan 25;00(0):1–4.
- Aubagio® [prescribing information]. Cambridge, MA: Sanofi Genzyme; 2017.